Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, AC Immune SA’s stock clocked out at $2.93, up 1.03% from its previous closing price of $2.9. In other words, the price has increased by $1.03 from its previous closing price. On the day, 0.16 million shares were traded. ACIU stock price reached its highest trading level at $2.99 during the session, while it also had its lowest trading level at $2.815.
Ratios:
To gain a deeper understanding of ACIU’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, BTIG Research on May 31, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 03 ’25 when ANDREA M.A PFEIFER bought 45,000 shares for $3.13 per share.
ANDREA M.A PFEIFER bought 35,000 shares of ACIU for $83,300 on Sep 12 ’25. On Jul 24 ’25, another insider, ANDREA M.A PFEIFER, who serves as the Officer of the company, bought 20,000 shares for $2.34 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACIU now has a Market Capitalization of 294758016 and an Enterprise Value of 191811584. For the stock, the TTM Price-to-Sale (P/S) ratio is 56.29 while its Price-to-Book (P/B) ratio in mrq is 3.29. Its current Enterprise Value per Revenue stands at 43.873 whereas that against EBITDA is -2.677.
Stock Price History:
The Beta on a monthly basis for ACIU is 1.61, which has changed by -0.14705884 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, ACIU has reached a high of $4.00, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is -6.81%, while the 200-Day Moving Average is calculated to be 26.58%.
Shares Statistics:
It appears that ACIU traded 286.67K shares on average per day over the past three months and 241900 shares per day over the past ten days. A total of 88.04M shares are outstanding, with a floating share count of 60.78M. Insiders hold about 38.57% of the company’s shares, while institutions hold 25.05% stake in the company. Shares short for ACIU as of 1763078400 were 1618509 with a Short Ratio of 5.65, compared to 1760486400 on 1576999. Therefore, it implies a Short% of Shares Outstanding of 1618509 and a Short% of Float of 3.39.
Earnings Estimates
The dynamic stock of AC Immune SA (ACIU) is currently attracting attention from 2.0 analysts actively involved in rating its market status. Analysts are recommending an EPS of between -$0.69 and -$0.7 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is -$0.61, with 2.0 analysts recommending between -$0.5 and -$0.71.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for ACIU’s current fiscal year. The highest revenue estimate was $6M, while the lowest revenue estimate was $3.23M, resulting in an average revenue estimate of $4.43M. In the same quarter a year ago, actual revenue was $27.31MBased on 3 analysts’ estimates, the company’s revenue will be $32.75M in the next fiscal year. The high estimate is $90M and the low estimate is $3.24M.
